Introduction
Most current methods for quantifying drug concentrations in tissue are invasive and usually require tissue extraction, making them unsuitable for real-time dosimetry. An important potential application of optical pharmacokinetics (OP) is for the dosimetry of photosensitizers for photodynamic therapy (PDT). This paper addresses the use of OP, a noninvasive white-light spectroscopic measurement collected via ā ber-optic probe, for the quantitative monitoring of in vivo tissue concentrations of PDT drugs that absorb in the visible (vis) and near infrared (NIR) region. 1 Previous work focused on chemotherapy agents 1 , 2 and topical photodynamic agents. 3 In this paper, we describe novel applications of the OP method in assessing the concentration of a systemically administered photosensitizer and the correlation between chemical measurements in less-accessible internal organs and OP measurements in a more accessible organ (the mouth).
For very small source-detector separations of ber-optic probes (<500 microns), in the technique known as elastic scattering spectroscopy (ESS), diagnostic signatures have been shown in a number of disease/organ systems 4 À 6 and can be used to extract the intrinsic optical properties of the super¯cial layers. 7 For larger source-detector separations (>4 mm), methods based on the di®usion equation can extract the optical properties, but these methods provide average values for larger tissue volumes, thus lacking site speci¯city. Also, most systems for doing this are limited to the red and NIR because absorption by water and hemoglobin is too strong at other wavelengths. 8 À 10 For intermediate source-detector separations, the OP method o®ers the opportunity for the quantitative measurement of absorption, due to speci¯c chromophore absorption characteristics, enabling greater sensitivity than ESS, while retaining highly localized site-speci¯city. If the¯ber separation is in the range 1.6À2.5 mm, the geometry is such that the e®ective photon path length is almost insensitive to the (reduced) scattering coe±cient of the tissue, 0 s . The path length is hence independent of morphological changes within the tissue, yet is long enough for sensitive detection of small concentrations of strongly absorbing chromophores. 1 À 11 This facilitates the use of Beer's law for extraction of the absorption coe±cient, independent of scattering properties. Within this range of separations, the depth of sensitivity, as well as the sensitivity to small drug concentrations, increases for larger separations. The optimum separation may be chosen to best suit the thickness of the tissue being sampled. This scattering-independent path length means that the concentration can be extracted in a straightforward fashion. In tissue, the path length is approximately 5 mm and the sampling volume is presumed to be close to 1 mm 3 for this¯ber geometry and wavelength range (650À700 nm). In this study, a¯ber separation of 1.7 mm was chosen. Other¯ber separations were not studied.
PDT is a chemotherapeutic technique used to treat a range of cancerous and pre-cancerous conditions. 12 The patient is administered a photosensitizer (PS) either topically or systemically, and the targeted area is illuminated, usually with laser light. The PS is excited to a chemically active state, which combines with oxygen in the tissue to create cytotoxic species (e.g., singlet oxygen, superoxide), causing local cellular damage whilst typically leaving connective tissue intact. E®ective therapy depends on the concentration of photosensitizer, of oxygen, and photoactivating light at every point in the target tissue. A real-time measurement (minimally invasive or noninvasive) of PS concentration in the target region would thus enable more predictable cytotoxicity, assuming available oxygen and light. PS biodistribution, even within a healthy organ, can be markedly heterogeneous, and site-speci¯c measurements can provide valuable information.
The OP technique could be particularly valuable where the PDT is to be carried out interstitially under image guidance 13 À 15 on an inaccessible organ 16 ; if OP were extended to correlate measurements in the mouth (or other accessible organ) with PDT e®ects in a less-accessible organ, the technique could improve the e±cacy of therapy even further. 17 This paper addresses these possibilities with studies using the photosensitizer aluminium disulfonated phthalocyanine (AlS 2 Pc), chosen for its stability, solubility, ease of administration, and low toxicity in the absence of light. AlS 2 Pc displays a strong, wellde¯ned absorption band around 670À675 nm, with a line width of about 10 nm. 18 Its extinction coe±cient at this wavelength reaches 2 Â 10 5 M À1 cm À1 , compared to 3 Â 10 3 M À1 cm À1 for por¯mer sodium (Photofrin) and 3 Â 10 4 M À1 cm À1 for mTHPC (meso-tetra(hydroxyphenyl)chlorine. Foscan), other PS drugs in clinical use. Even adjusting for the typical molar concentrations used clinically, AlS 2 Pc gives a much stronger optical signal, and our group has extensive pre-clinical experience with this PS. 19 , 20 Work with other phthalocyanines has begun recently in the treatment of cutaneous t-cell lymphoma, 21 and many aspects of our study can be generalized to a variety of agents.
Methods and Materials

Photosensitizer
AlS 2 Pc powder (Frontier Scienti¯c Ltd., UK) was used to prepare the required concentration for intravenous injection by dissolving 1 mg into 50 L of 0.1 M sodium hydroxide (Sigma-Aldrich, UK) and then adding phosphate bu®ered saline (SigmaAldrich, UK) to make the required volume.
Phantom measurements
To test the limits of sensitivity of our equipment and examine any path length e®ects, we prepared optical tissue phantoms using 37 mL Phosphate Bu®ered Saline (PBS), 2 mL of 20% Intralipid r , and varying quantities (0.01, 0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25, 50, and 75 g/mL) of AlS 2 Pc. The peak height of the negative-log-ratio to a linear baseline interpolation (described below) was examined. Previous work 1 has estimated the path lengthdependence on absorption coe±cient a in this geometry, using the expression for the path length L
and so the phantom data absorbance A can be¯tted using the function
where C is a constant that accounts for inadequacies in the baseline¯t, which lead to nonzero absorbance measures in the absence of added absorbers. Previously, 1 parameters x 0 ; x 1 , and x 2 were measured as 0.6, 1.3, and 3.57 cm, respectively. Another way to capture this deviation from linearity is to use a powerlaw¯t, where Að a Þ ¼ mð a Þ n , as utilized in Ref. 2.
Animal model
Wistar rats (180À220 g, Harlan UK Ltd., Blackthorn, Oxfordshire, UK) were housed under diurnal lighting conditions and allowed food and tap water ad libitum. Rats were anesthetized with 2% halothane (Merial Animal Health Ltd., Harlow, UK) in oxygen for induction and maintenance throughout surgery, with the animals breathing spontaneously. Analgesia was administered subcutaneously 1 h prior to surgery (Vetergesic r , buprenorphine hydrochloride, Reckitt Benckiser Healthcare Ltd., Hull, UK).
All procedures were carried out under the authority of project and personal licences granted by the UK Home O±ce and the UKCCCR Guidelines (2010).
OP measurements on tissues
Rats were sensitized with dosages of 0 (control animals), 0.1, 0.2, 0.25, 0.5, 1.0, or 2.5 mg/kg of AlS 2 Pc as a bolus injection into the tail vein. At 1 or 24 h later (immediately for control animals), OP measurements were performed on shaved abdominal skin, thigh muscle with skin removed, oral mucosa and, after laparotomy, on liver, glandular stomach, and colon. Three rats were used for each drug dose and each time interval; the intervals were chosen to see whether di®erent biodistributions a®ected the quality of the results. At 1 h, the drug will still have a signi¯cant proportion within the vasculature, whereas by 24 h it will reside mainly within the organ parenchyma. 22 The OP¯ber-optic probe (described below) was positioned by means of a micromanipulator, so that it was just touching the surface of the organ under examination. On each organ, 10 separate positions were chosen, with 4 OP measurements being taken at each position (i.e., 40 spectra per organ). When only a small thickness of tissue was being investigated, a piece of matt black card was placed under the tissue to minimize the e®ects of light that passed through the tissue and out the far side, and might be scattered back from other adjacent tissues.
Immediately after the OP measurements were completed, the animals were killed, and the OP measurements were repeated post mortem in the same organs. Tissue samples were collected from each animal and stored at À20 C for alkaline extraction of AlS 2 Pc. 
Alkaline extraction of AlS 2 Pc from tissue
Finely-cut thawed tissue samples, including controls of each organ from unsensitized animals, were added to 0.1 M sodium hydroxide (NaOH, SigmaAldrich, UK) at a ratio of 0.1 g into 10 mL NaOH. From each animal, four samples of each organ were processed. The tissues in NaOH were incubated in a water bath at 50 C for 6 h in darkness to allow cell breakdown. The samples were shaken approximately halfway through the incubation period to ensure adequate breakdown of cell structures to release the AlS 2 Pc. AlS 2 Pc concentrations in the resulting solution were measured by spectro°uorimetry (PerkinElmer LS50 Luminescence Spectrophotometer). The solutions were loaded into 96-well plates, and°uor-escence was measured using a Perkin-Elmer LS50 luminescence spectrometer at excitation and emission wavelengths of 605 and 675 nm, respectively. A slit width of 10 nm and an integration time of 1 were set for both excitation and emission. The emission was long-pass¯ltered to eliminate scattered light at wavelengths shorter than 645 nm (RG645 Schott long-pass¯lter). The concentration of AlS 2 Pc in each specimen could then be calculated against a standard curve. A standard curve was prepared each time a chemical extraction (CE) was undertaken using 0.1 M NaOH solutions with known concentrations of AlS 2 Pc. Calibration curves were plotted for three ranges of concentration: 0 to 0.5, 0 to 0.1 and 0 to 0.01 g/mL; for the liver, in which higher concentrations of drug accrued, a larger-range calibration curve was constructed, covering 0 to 100 g/mL.
A molecular weight of 735.08 g/mol was used for calculations of AlS 2 Pc concentrations.
OP system
The OP collection apparatus consists of a light source, delivery and collection¯bers, a spectrometer, and a laptop computer, see Fig. 1 . OP data were collected from tissues using a pair of¯bers inside a catheter. The tip of the catheter was positioned to be just touching the tissues to be interrogated and, at the tip, the¯ber centers were 1.7 mm apart, which was chosen on the basis of previous publications as discussed in Sec. 
We can further split AðÞ into photosensitizer and tissue components
The tissue attenuation A tissue will include tissue absorption and scattering, in particular the e®ects of (oxyhemoglobin (HbO) and deoxyhemoglobin (Hb)). From Eqs. (5) and (6) A where c PS is the photosensitizer concentration, hLi is the e®ective mean photon path length, and ½PS ðÞ is the extinction coe±cient of the photosensitizer. Our OP measure will be based on the quantity A PS (see below).
If it were necessary to take baseline optical measurements in di±cult-to-reach sites prior to drug administration, this would limit the clinical use of the technique in some clinical applications, and even when such a measurement is possible, time variation of the tissue properties and errors in co-registration mean that the tissue component will not be completely removed from the spectrum by the process. It is therefore desirable to use methods to estimate the tissue contribution from spectra taken from sensitized animals, without the need for a reference spectrum from an unsensitized animal.
Optical pharmacokinetic metrics
In this study, the OP metrics we considered to measure the drug absorption were AUC*, AUC, y and peak-¯tting metrics (A 1 and A 2 ). Area-under-curve (AUC) methods (AUC* and AUC y ) calculate the area under a peak over a speci¯ed wavelength range, which inherently incorporates some noise-averaging. Each AUC technique used a di®erent method for baseline removal, detailed below. Finally, a peaktting method was tried, which uses aqueous AlS 2 Pc spectra to¯t to animal data; this should account for any spectrally shifted (but not broadened or otherwise modi¯ed) components in the in vivo drug spectrum, but is more analytically complex. These approaches are detailed below.
The absorption feature of interest in the AlS 2 Pc spectrum is the strong peak at 672 nm. 23 The tissue absorption at these wavelengths can be estimated by linear interpolation of the spectrum between two points (650À700 nm), shown in Fig. 2 . We call this function I linear ðÞ. In this range we expect the baseline to be smooth but not linear, so we would expect a¯nite (positive or negative) area, even for zero AlS 2 Pc. We de¯ne 
We use an area under curve measure, AUC*, de¯ned as:
These limits lie within the full width of the drug peak, chosen in order to capture the local baseline and any possible wavelength shifts and to sample ā xed proportion of the drug absorption peak. Choosing wider limits would mean modulations in the baseline nonlocal to the central drug peak, which could distort the interpolation of the local baseline. Outlier points [points over three standard deviations (SDs) from the animal mean] were iteratively removed.
Control animals and hemoglobin spectrum removal
Ratioing spectral data against a characteristic spectrum of the same organ from unsensitized animals was carried out to remove a large proportion of the baseline features common to all animals. An average was formed over¯ve control animals (10 sites per organ, four measurements per site) for each organ to produce the characteristic spectra. Spectra from AlS 2 Pc sensitized animals could then be divided by this spectrum, and the negative logarithm taken to give the control-ratio-log (CRL) attenuation
The features present in A CRL ðÞ will be due to di®erences between the control animal and the sensitized animal. This will include changes in the hemoglobin saturation and perfusion, the drug signal, and to a less signi¯cant extent, in absorption and scattering due to other e®ects. Oxyhemoglobin (HbO) and deoxyhemoglobin (Hb), the largest contributors to absorption changes, were¯tted to A CRL ðÞ using spectral Hb/HbO extinction coe±-cients (" HbO=Hb Þ, with ÁC HbO and ÁC Hb as¯tting parameters, representing changes in concentration of HbO and Hb (and a constant o®set to compensate for any changes in intensity of the raw spectra). The hemoglobin extinction coe±cients, both HBO and Hb were taken from the Oregon Medical Laser Centre website.
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A fit ðÞ ¼ ÁC HbO " HbO ðÞ þ ÁC Hb " Hb ðÞ þ : ð12Þ
This¯t was carried out in Matlab using their standard curve-¯tting toolbox which utilizes a LevenbergÀMarquardt approach. The hemoglobint region (520À600 nm and 750À900 nm) was set outside the AlS 2 Pc absorption peak. The resultinḡ t was subtracted from the data to leave a residual spectrum. This was interpolated from 625 to 725 nm, and the line was subtracted to remove any linear baseline remaining (from scatter and any other chromophores). The remaining spectrum, 
Peak position and line shape
There were variations in both the line shape and in the peak absorption wavelength of the measured drug. Suspecting that this might be due to a chemical shift, we attempted to¯t the observed absorption, A Ã with the function
where PthðÞ is the aqueous AlS 2 Pc spectrum and n is a factor shifting the central wavelength of the AlS 2 Pc peak. The n terms represent a local baseline, due to tissue absorption and scattering e®ects (an attempt was made to¯t this baseline with hemoglobin extinction coe±cients, but did not provide an accurate or as general a¯t). A 1 and A 2 are the contribution from each peak. Figure 3 shows data taken from the colon and¯tted using this method. One peak is typically blue-shifted by 0À5 nm, and the other red-shifted by 12À15 nm. Similar results have been reported elsewhere 25 and this will be covered in more detail in the discussion.
Because the line width of each peak did not appear to change, the quantities A 1 and A 2 can be combined to give a measure of total drug concentration, A 12 :
Note that the e®ects of wavelength-dependent line width changes are not explicitly incorporated, although the baseline-¯t might be expected to compensate for this to some degree.
Results
Phantom study
The results are shown in Fig. 4 , where the absorbance signal of AlS 2 Pc is signi¯cant and well-separated above 0.1 g/mL, with an s=n ratio of >10. We were unable to reproduce the path length parameters produced in Ref. 1, and these parameters exhibited sensitivity to the concentration range considered. In part, this is due to aggregation e®ects of AlS 2 Pc, so we constrained our concentration range to typical physiological values for the majority of organs. Con¯ning ourselves to the 0À5 mg/kg range yields Figure 5 shows the correlation between the OP AUC* and CE measurements for colon, skin, muscle, mouth, and stomach. At moderate AlS 2 Pc concentrations, there are strong correlations between CE and OP in most organs at 1 and 24 h ( Table 1 ). The correlation is well-described by a linear regression, passing close to the origin -this suggests little zero-point error is introduced by using a linear baseline interpolation. Fitting this relationship using power-law functions proved problematic. Data from the muscle, skin and stomach gave power coe±cients greater than or equal to 1, i.e., the¯t converged to a linear function, or gave nonphysical results (see discussion). The mouth and colon showed slightly improved¯ts when a power law was applied; for 1 h, 24 h and all data categories together, the colon exhibited powers of 0.8, 1.2 and 0.6, respectively; and the mouth 0.6, 1.3 and 0.7; clearly the 24 h data is not giving a physical¯t to the data. Figure 6 shows both measures, A 1 þ A 2 , from the peak-¯tting function, expected to cover all drug environments. The colon and the mouth alone display a power-law-like behavior, and so power-law ts are included. The powers for the colon (for 1 h, 24 h, and all times together) are 0.7, 1.06, and 0.6. For the mouth, the power coe±cients are 0.6, 1.0, and 0.65. For the other organs, these coe±cients approached or exceeded unity. Table 1 summarizes the data correlating OP measurements with CE using AUC*, AUC y , and A 1 þ A 2 , and the correlation of AUC* in the mouth with CE in di®erent organs within the same animal. 1 and 24 h data are shown separately (as AlS 2 Pc may have di®erent biodistributions at these times) and together (all data points, not grouped by time). The results using AUC* and AUC y were almost identical. Similarly, the OP results from post-mortem versus (alive) in vivo tissues showed close similarity (data not shown), with R 2 values >0.9 being typical for correlations between the two.
Tissue measurements
One of the aims of this project was to make measurements in an easily accessible organ like the mouth to quantify drug levels in less accessible organs like the stomach. This is illustrated in Fig. 5(f) , which correlates CE in the stomach with OP AlS 2 Pc signals in the mouth. Table 1 summarizes these correlations between measurements in the mouth with those in the range of organs studied. The liver data shows relatively weak correlation, but the other organs have R 2 > 0:75 at 1 h. At 24 h, the correlation is low in the muscle (possibly due to low drug levels in that organ), but with R 2 > 0:8 for all others.
In the liver, much higher AlS 2 Pc concentrations are seen compared with the other organs. The low OP values documented 1 h after AlS 2 Pc administration are probably due to the exceptionally high drug concentration at this time causing shadowing and dimerization (see discussion). Figure 7 shows how poorly the extinction coe±cient method correlates for the liver, due to these e®ects. In vivo Optical Pharmacokinetics 105 Table 1 .
R 2 values for OP-CE correlation, including correlation of CE in each organ with AUC* measured in the mouth. 
Discussion
Chemical extraction -OP correlation
One of our aims was to determine whether Optical Pharmacokinetics could be used as a minimally invasive technique to measure the concentration of photodynamically active drugs, photosensitizers, in vivo in real time, with a particular emphasis on estimating the level of photosensitizers in target tissues at the time of light delivery for PDT. The OP technique has proven successful in phantom measurements, where OP can comfortably detect drug at 0.1 g/g (100 ng/g), but the in vivo situation proved to be more complicated. The uncertainty inherent in the Chemical Extraction measurements is at least 0.1 g/g, giving a lower limit of quantitation (LLQ) of at least 0.3 g/g; the uncertainty in each AUC* measurement is of order 0.01 g/g, but the statistical scatter about the line of best¯t is somewhat larger. At larger concentrations, as measured by CE, the variance can be extremely large (residuals > 1 g/g), and even at the lowest values, CE gives a variance of typically 0.1À0.3 g/g. However, because this is similar to the absolute value, it is di±cult to place a LLQ on the in vivo OP measurements based on the CE data. It appears the variance within individual OP sites is a factor of 10 lower than the CE measure, and the scatter about the line of best¯t is similar in magnitude to the error in the CE measure, implying substantial variation between individual measurement sites within organs. To fully test the LLQ sensitivity of OP, it will be necessary to improve the sensitivity of CE by at least a factor of 10. This could be achieved following recent improvements in the technique, such as using the Solvable TM (Perkin Elmer) Chemical Extraction medium, which typically requires¯ve times less solvent (increasing signal vefold) 26 and more sensitive°uorimeters. Alternatively, either taking measurements using cuvettes or photon-counting detectors would signi¯cantly improve the sensitivity of the assay, but would increase the collection time and cost, respectively. The method of HPLC utilized by other researchers (for example, Ref. 2) is extremely sensitive (drug concentration as low as 0.03 M) and would provide another alternative. Unfortunately, we did not have access to such equipment.
Phantom measurements showed a nonlinear OP/ concentration curve, indicative of the absorption dependence of the path length. While previous studies 1 , 2 show a similar nonlinear behavior, the parameters we extracted from our measurements were somewhat di®erent to those previously reported; for example Mourant et al., 1999 1 used a much smaller range of drug concentrations than ourselves; we were able to observe a strong concentrationdependence of the path length-¯tting parameters.
For the majority of the in vivo data, power-law ts provide no¯tting advantage, and in many cases utilize a power coe±cient $1, or even worse, >1; this case predicts an increasing path length with increasing absorption, and can be interpreted as ā tting artefact due to large statistical scatter in the dataset. This can also be ascribed to inter-and intra-animal variations. Based on our phantom measurements, a tissue absorption baseline into which 5 g/g of AlS 2 Pc is introduced will result in a 20% reduction in signal; the other sources of variance and uncertainty at present dwarf this change, explaining why the nonlinearity of the¯t is not wellpronounced in much of the data.
At high concentrations, one must consider dimerization, where two AlS 2 Pc molecules are weakly bound together; the resulting organic complex has a broader, weaker extinction coe±cient (reported as a feature centered around 670 nm with a full width half maximum in excess of 100 nm 18 , 23 ). The CE process ensures that any AlS 2 Pc is fully monomerized at the time of the°uorescence measurement, giving a measure of the total AlS 2 Pc, but in vivo dimerization will mean that the OP AUC* integral will not be an accurate re°ection of the total drug concentration. The dimer form is signi¯cantly less active in photodynamic therapy, 18 so it may be bene¯cial that OP preferentially detects the main photoactive component. However the situation is complex as there is also evidence that the PDT process can cause remonomerization, so one cannot completely ignore the nonmonomeric forms. 27 Analysis of the line shape of the AlS 2 Pc absorption peak in vivo showed it to be composed of two spectral components, one blue-shifted by 0À5 nm and one red-shifted by 12À15 nm from the spectral locations of the single peak of AlS 2 Pc seen in aqueous solution. The 0À5 nm blue-shifted component is very similar to the AlS 2 Pc spectrum we see in a cuvette for an aqueous solution (where small shifts can be induced by di®erent saline and pH environments). The component that is red-shifted is consistent with a similar shift seen by previous workers in murine blood. 25 , 28 This points to the drug existing in two distinct chemical environments, and passing from the red-shifted to the slightly blueshifted compartment between the 1 and 24 h measurements (the red-shifted peak is much more dominant at the 1 h time point in all organs except for the liver). However, there are a number of factors pointing to this e®ect not being solely due to localization of AlS 2 Pc in blood: a phantom that utilized whole blood exhibited no red-shifted component (not shown); and previous workers saw only small red shifts when adding an excess of human serum albumin to phthalocyanine in solution. 29 In work carried out on murine ascites, a concentrationdependent red shift was seen, which was attributed to binding to nonspeci¯c biological substrates. 25 It was noted that intracellular AlS 2 Pc does not show a spectral shift of this nature, although encapsulation in lysosomes signi¯cantly increases the local concentration, creating dimerized species. 30 This compartmentalization measurement o®ers a promising future avenue for research, especially in the¯eld of Photochemical Internalization. 27 
Conclusions
In conclusion, OP shows promise for measuring tissue concentration of photosensitizers in real time and so for better real-time prediction of the extent of necrosis in photodynamic therapy.
